Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1977 2
1981 1
1982 2
1983 3
1984 4
1985 2
1986 1
1987 5
1988 1
1989 6
1990 6
1991 7
1992 1
1993 5
1994 2
1995 2
1996 6
1997 2
1998 4
1999 3
2000 3
2001 4
2002 7
2003 1
2004 2
2005 4
2006 6
2007 4
2008 7
2009 5
2010 2
2012 4
2013 3
2014 4
2015 1
2016 5
2017 4
2018 4
2019 1
2020 7
2021 2
2022 4
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

144 results
Results by year
Filters applied: . Clear all
Page 1
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C, Gravis G, Fléchon A, Soulié M, Guy L, Laguerre B, Mottet N, Joly F, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Pfister C, et al. Eur Urol. 2021 Feb;79(2):214-221. doi: 10.1016/j.eururo.2020.08.024. Epub 2020 Aug 28. Eur Urol. 2021. PMID: 32868138 Clinical Trial.
Most of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 toxicities concerned hematological toxicities, reported for 129 (52%) patients in the dd-MVAC group and 134 (55%) patients in the GC group. ...Higher toxicity regarding asthenia and …
Most of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 toxicities concerned hematological toxicities, r …
Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.
Campbell JM, Bateman E, Stephenson MD, Bowen JM, Keefe DM, Peters MD. Campbell JM, et al. Cancer Chemother Pharmacol. 2016 Jul;78(1):27-39. doi: 10.1007/s00280-016-3043-5. Epub 2016 May 3. Cancer Chemother Pharmacol. 2016. PMID: 27142726 Review.
Toxicity outcomes included different forms of hematologic, ectodermal and hepatic toxicities. ...However, significant associations were found between the MTHFR C677T allele and; hepatic toxicity, myelosuppression, oral mucositis, gastrointestinal …
Toxicity outcomes included different forms of hematologic, ectodermal and hepatic toxicities. ...However, significant a …
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Ferreri AJ, et al. Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6. Lancet Haematol. 2016. PMID: 27132696 Clinical Trial.
Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy (the MA …
Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addres …
MTHFR gene polymorphisms and methotrexate toxicity in adult patients with hematological malignancies: a meta-analysis.
Zhao M, Liang L, Ji L, Chen D, Zhang Y, Zhu Y, Ongaro A. Zhao M, et al. Pharmacogenomics. 2016 Jun;17(9):1005-17. doi: 10.2217/pgs-2016-0004. Epub 2016 Jun 8. Pharmacogenomics. 2016. PMID: 27270164
BACKGROUND: MTHFR gene polymorphisms has been shown to be associated with methotrexate (MTX) toxicity in adult hematological malignancies; however, the results remain inconclusive. ...MTHFR A1298C polymorphism was not significantly associated with hepatic and …
BACKGROUND: MTHFR gene polymorphisms has been shown to be associated with methotrexate (MTX) toxicity in adult hematologica …
Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature.
Balak DMW, Gerdes S, Parodi A, Salgado-Boquete L. Balak DMW, et al. Dermatol Ther (Heidelb). 2020 Aug;10(4):589-613. doi: 10.1007/s13555-020-00409-4. Epub 2020 Jun 11. Dermatol Ther (Heidelb). 2020. PMID: 32529393 Free PMC article. Review.
Long-term treatment with acitretin could be associated with skeletal toxicity and hepatotoxicity, although evidence for skeletal toxicity is mixed and hepatotoxicity is rare, particularly at low doses. ...Long-term methotrexate treatment is associated with he …
Long-term treatment with acitretin could be associated with skeletal toxicity and hepatotoxicity, although evidence for skeletal t …
Upper gastrointestinal bleeding secondary to toxicity by anthracyclines, cytarabine and methotrexate in a patient with acute lymphoblastic leukemia.
García Martínez A, Aguilar Martínez JC, Campos Gonzaga L, Mateos Millán D. García Martínez A, et al. Rev Esp Enferm Dig. 2022 Jun;114(6):363-364. doi: 10.17235/reed.2022.8639/2022. Rev Esp Enferm Dig. 2022. PMID: 35100805 Free article.
A 60-year-old male patient with no medical history but acute lymphoblastic leukemia was admitted in the hematology ward for chemotherapy treatment (methotrexate, cytarabine, fludarabine and idarubicin). ...Given the multiplicity of lesions, medical treatment with hi …
A 60-year-old male patient with no medical history but acute lymphoblastic leukemia was admitted in the hematology ward for chemother …
High dose methotrexate in adult Egyptian patients with hematological malignancies: impact of ABCB1 3435C > T rs1045642 and MTHFR 677C > T rs1801133 polymorphisms on toxicities and delayed elimination.
Ebid AIM, Hossam A, El Gammal MM, Soror S, Mangoud NOM, Mahmoud MA. Ebid AIM, et al. J Chemother. 2022 Oct;34(6):381-390. doi: 10.1080/1120009X.2021.2009723. Epub 2021 Dec 13. J Chemother. 2022. PMID: 34895107
High dose methotrexate (HDMTX) is an essential agent in chemotherapeutic regimens used in various hematological malignancies in Egyptian adults. ...Eighty-nine percent of the patients diagnosed with acute lymphoblastic leukemia 'ALL', 5% of the patients had B cell n …
High dose methotrexate (HDMTX) is an essential agent in chemotherapeutic regimens used in various hematological malignancies i …
Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia.
Garré ML, Relling MV, Kalwinsky D, Dodge R, Crom WR, Abromowitch M, Pui CH, Evans WE. Garré ML, et al. J Pediatr. 1987 Oct;111(4):606-12. doi: 10.1016/s0022-3476(87)80131-2. J Pediatr. 1987. PMID: 2958611
Children with Down syndrome and acute lymphocytic leukemia (ALL) have poor tolerance to antineoplastic drugs, including methotrexate (MTX). We evaluated MTX pharmacokinetics and toxicity in five patients with Down syndrome and ALL who had received multiple high dose …
Children with Down syndrome and acute lymphocytic leukemia (ALL) have poor tolerance to antineoplastic drugs, including methotrexate …
Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
Patiño-García A, Zalacaín M, Marrodán L, San-Julián M, Sierrasesúmaga L. Patiño-García A, et al. J Pediatr. 2009 May;154(5):688-93. doi: 10.1016/j.jpeds.2008.11.030. Epub 2009 Jan 21. J Pediatr. 2009. PMID: 19159907 Free article.
RFC1 expression was moderately decreased in samples with poor histologic response to preoperative treatment (P = .053). Patients with osteosarcoma with G3/G4 hematologic toxicity were more frequently TT than CT/CC for C677T/MTHFR (P = .023) and GG for A2756G/MTR (P …
RFC1 expression was moderately decreased in samples with poor histologic response to preoperative treatment (P = .053). Patients with osteos …
Altretamine.
Hansen LA, Hughes TE. Hansen LA, et al. DICP. 1991 Feb;25(2):146-52. doi: 10.1177/106002809102500209. DICP. 1991. PMID: 1905441 Review.
However, few randomized trials have evaluated the contribution of altretamine in these multiagent combinations. Dose-limiting toxicities include gastrointestinal (nausea, vomiting, anorexia), hematologic, and neurotoxic (peripheral neurotoxicity). The therape …
However, few randomized trials have evaluated the contribution of altretamine in these multiagent combinations. Dose-limiting toxicities …
144 results